Login to Your Account

Heplisav Data Disappoint; Dynavax Stock Sinks 19%

By Marie Powers

Thursday, July 21, 2011
Dynavax Technologies Corp. reported Wednesday that top-line data from the Phase III trial comparing its investigational hepatitis B vaccine Heplisav met all three clinical endpoints, demonstrating noninferiority, superiority and safety in comparison to the marketed hep B vaccine Engerix-B (GlaxoSmithKline). Nevertheless, investors failed to respond with enthusiasm, perhaps reflecting nervousness about a second piece of news regarding the company's consistency analysis of manufacturing data.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription